Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
The Pharmacogenomics Journal|September 20, 2006
Pharmacogenetics of warfarin: current status and future challengesM Wadelius, M PirmohamedClinical Pharmacology and Therapeutics|November 14, 1997
Induction of CYP2D6 in pregnancyM Wadelius, E Darj, G Frenne, et al.Pharmacogenetics|March 30, 2000
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosisM Wadelius, E Stjernberg, B E Wiholm, et al.Pharmacogenetics|December 11, 1999
Prostate cancer associated with CYP17 genotypeM Wadelius, A O Andersson, J E Johansson, et al.Clinical Pharmacology and Therapeutics|October 21, 2011
A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapyP J Avery, A Jorgensen, A K Hamberg, et al.Journal of Medical Genetics|October 10, 1997
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazidC A Smith, M Wadelius, A C Gough, et al.Human & Experimental Toxicology|May 16, 2008
Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placentaM Rahi, T Heikkinen, J Hakkola, et al.The Pharmacogenomics Journal|December 17, 2003
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsM Wadelius, K Sörlin, O Wallerman, et al.The Pharmacogenomics Journal|February 24, 2010
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancerB Glimelius, H Garmo, A Berglund, et al.Clinical Pharmacology and Therapeutics|February 16, 2007
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapyA-K Hamberg, M-L Dahl, M Barban, et al.Pageof 3